Discussion on the mechanism of Shema Oral Liquid in the treatment of Coronavirus disease 2019 based on network pharmacology
FENG Jihong1 TAN Wangxiao2 ZHANG Shuo1 JIN Shiyuan3 BI Mingda2 QIN Yunpu2 ZHAO Kun4
1.Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China; 2.Chinese Medicine Research Institute, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;
3.Beijing Health School, Beijing 100053, China;
4.Hainan Zhongsheng Hemei Biopharmaceutical Co., Ltd., Hainan Province, Haikou 570100, China
Abstract:Objective To investigate the mechanism of Shema Oral Liquid in the treatment of Coronavirus disease 2019 (COVID-19). Methods The active components and targets of Shema Oral Liquid were searched by Chinese medicine pharmacology database and analysis platform (TCMSP). COVID-19 related targets were obtained from GeneCards database. The potential targets of Shema Oral Liquid in the treatment of COVID-19 were obtained by mapping the drug targets and disease targets for subsequent analysis. Protein-protein interaction (PPI) network and drug-component-target-disease network were constructed by STRING database and Cytoscape software, and disease and function analysis were carried out through Ingenuity Pathway Analysis (IPA). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was carried out by using STRING database. Results A total of 106 active components and 53 potential therapeutic targets of COVID-19 from 10 traditional Chinese medicines in Shema Oral Liquid were screened. The main active components included quercetin, luteolin, β-sitosterol, kaempferol, stigmasterol, etc., and the key targets involved MAPK3, TNF, IL-6, MAPK8, CXCL8, etc. The 53 therapeutic targets were mainly involved in cell death and survival, body injury and abnormality, inflammatory response and other biological functions. KEGG pathway enrichment resulted in 169 biological pathways, mainly involving IL-17, Toll-like receptor, HIF-1, TNF signaling pathways, etc. Conclusion Shema Oral Liquid may act on IL-6, TNF, MAPK8, CXCL8 and other targets through various active ingredients such as quercetin, luteolin, β-sitosterol, kaempferol, and then regulate multiple pathways such as IL-17, TNF, Toll-like receptor, and HIF-1 to treat COVID-19.
封继宏1 谭旺晓2 张硕1 金世元3 毕明达2 秦云普2 赵坤4. 射麻口服液治疗新型冠状病毒肺炎作用机制的网络药理学探讨[J]. 中国医药导报, 2021, 18(8): 4-9,24.
FENG Jihong1 TAN Wangxiao2 ZHANG Shuo1 JIN Shiyuan3 BI Mingda2 QIN Yunpu2 ZHAO Kun4. Discussion on the mechanism of Shema Oral Liquid in the treatment of Coronavirus disease 2019 based on network pharmacology. 中国医药导报, 2021, 18(8): 4-9,24.